{"name":"Urovant Sciences GmbH","slug":"urovant-sciences-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxQajk4Z1dpRUZvYmgxak10eGNsaWdLdkM5NHBlNWdrb3l6R3Z4cjliUnpyNjBNNGpONWpZcG04eWZqZ3UwWXZ0QTVmWkFmQmwtSktua2ZsLW1HSGQxejRtZU43emp4NUF5YlRGMDNmRXlwcTV4UVlFaXlKcXUwczR0Rk05V01BaGo3SmF0Z1YtM0NFemZsaGtCamNYRDJyWHhLSHVmV1JRZWpFWU9hbXMtRG5GMmtfcGN1RjN1RGxCREYyaEYwUDVJVDZldC1HWUtRdng0TGlQbkcwTlAyY09ZQVhITHdvSjVNWU5fSklJbzQySHhBSm5MYnVQVEt0Mlk3d2cyRXROb000ellfMTNRVWhvZTRCcGFCUUJFVFY1U3gzZER1ZFBNb0dRaw?oc=5","date":"2025-06-30","type":"earnings","source":"BioSpace","summary":"Sumitomo Pharma America and Former Professional Quarterback Rodney Peete Say it's Time to Go™ and Put Yourself First with Overactive Bladder Treatment Option GEMTESA - BioSpace","headline":"Sumitomo Pharma America and Former Professional Quarterback Rodney Peete Say it's Time to Go™ and Put Yourself First wit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxQbmcya0I1eXpqRmVpWVVSek5TRlotMFRkSl95azJqOTl3NE05R0FZc2o4eGxZTk5BWVJvZEpPQzNmNWlmSzE4SXpudVFXNVFpWExFdVllR0dUZW9aLXFQZnAwVnBlWmtWWVJJWDdoZkJvdmhrWUVsWXN3M19KUzVmb0hJNjdkbklKeDRnVFJCa082M2FDd3R4MmZ1YjVxMTVra0dobzFvdmg4NWpDSDZsWVdCNHhhTXZGeVVhVzFDRkx4YmtUZlVzT1FQR3F1QkNvM3ppbThlZVNHOG5XV2ZmSzZFTUZzWGFfSTRrS1VIbjRlcjhtRm9KN1hzYzI?oc=5","date":"2025-04-29","type":"trial","source":"PR Newswire","summary":"Sumitomo Pharma America Presents New Data on Vibegron at the 2025 American Urological Association Annual Meeting - PR Newswire","headline":"Sumitomo Pharma America Presents New Data on Vibegron at the 2025 American Urological Association Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNUnVHNVF2dno3TDNNdERfcm41c3ExeGg3VHktY1B5MDAwSzR6WkJkRTVMVHUxWHVQYWdmSXhyN0ZaR3RfbFhHQVhoSnNvcUVXbjI4MzVkLXgzQmpWT0w5ZkJFWjQzQnVtWjFiUzFSeGlHcTZQVzFURE1qYURlX2xQdkkxT2s2cEtlcE9HWmZ6NDg2V3lVMHpQY2l4MEVFeTRsbVRz?oc=5","date":"2025-03-28","type":"pipeline","source":"Bloomberg Law News","summary":"Sumitomo Pharma Sues to Block Two Copies of Gemtesa Bladder Drug - Bloomberg Law News","headline":"Sumitomo Pharma Sues to Block Two Copies of Gemtesa Bladder Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxPMTB2Nk9mRk55cjlSSnhfWnM5UGlUTi1vRktKT0dEN3pweHRNUE5OUVl2dzc4WU9zZVpyajJhUWowMkZjbGtBdDI1V1ZpcVJnSFVjQkJ0Mnh4SnoxSEd1elVYWGxsNVNkNDYwaHk2Nzl5SnlzWm45dWxDZVFtUGhFNlotQTRmZmt0ZEhPZl91TS0yVjY3cTNYeU5sNDU5RlNLN05rcjVYUnc5YkxUbENYOXV1TVdIQXBoVE93SXRHbXQyVHN1U1Z1ck8yaW5MbUlHeFlNT29Qc0ZuZ2NZYmxacG5TTVhKVVVjTE5nNjA0a0N0czZHZEJvMEV1UFE5RDBoYnJBaGw0R2ZxVkRWWWc2amNHVVAxaUQzRklRWUI3S0F4TW9xTWlxSE4wazkwS3Bsa3lWQVNyMklMd3RUbHBqcjVVZlRzX0hpUDRSek9oMWk5RTA?oc=5","date":"2024-12-23","type":"regulatory","source":"PR Newswire","summary":"Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia - PR Newswire","headline":"Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron) for Men with Overactive Bladder Symptoms Rece","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxNakoxWUxOcGlwMm1SMUgwdTdudk1DVjA2cndmTFNTZWJEN29EbXVCTTdGUGJoVUlWM1R6YmNsdjhFS0V2dlJtSEp0dFR5M2lDaVZndGY5cTZfeVBWc2FiU1BuRlNSR0h5R2F2QlNIYVByZFJiTVdfLWhsdnVpTHJXZjMxSTNBa2V6SVFac2VwblcwZ2NpME8xNXM3T0lhVk1FOHNNZFc2MEVXX3Y3bkl3UUVvQXAtN0VTS3QtRUpSaUc4YmFCUktvZ0p2QTVvOXJHWjByREhDemkxcHBVd0hYM29JMHZ3UQ?oc=5","date":"2024-07-01","type":"regulatory","source":"BioPharma APAC","summary":"European Commission Approves OBGEMSA™ (Vibegron) for Overactive Bladder Treatment by Pierre Fabre Laboratories - BioPharma APAC","headline":"European Commission Approves OBGEMSA™ (Vibegron) for Overactive Bladder Treatment by Pierre Fabre Laboratories","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2024-05-13","type":"regulatory","source":"PR Newswire","summary":"Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia - ","headline":"Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men with Overactive Bladde","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNRGZtMnoxaS05Ry1rY1MtVWlwQkJWMkdWcUFVQl8zOVM2OHZpbEtSRm42YzdzTkV6Qzd2TUQxRHpUZ3R0eFBsSWxaU1FsOXlfNWhmTlotVmFzVUh1ckY5Q0RKS0FsN01UdWt2eHhjakdRUUNENHFFOGRsQkhtTUdjc2lVZW91RlQwZFVLbjl3SEJfcHBYRUxFTFV0ZmRhajhHYkZUcG5zOUhvSlBFQ0wwN0lkU2R3dmxXazB1a191Y0ZWV0VveHcxWWRTV2xpZw?oc=5","date":"2024-05-07","type":"trial","source":"PR Newswire","summary":"Sumitomo Pharma Presents Urology and Oncology Data at AUA 2024 Annual Meeting - PR Newswire","headline":"Sumitomo Pharma Presents Urology and Oncology Data at AUA 2024 Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPS242U1BSRHl3QVJicWYzVnRfcXlEYUpMQnN3Ym9RQno0bS0yaXNENk5FWkpyb0JzRm83b0M5UHhjcUxIZDY1MDNPSDFyUmhOLXYySWJhbUZhWUdFbi11cTljOHhsTTdjMmJ6Qlh5bThWUFVhSUhHc0dfU0t6bkh4dWotZWFzYlV3Ml9lSXluRHZFSzU4eUtOXzFTRzZUWndldy1Jb3NPMGFwNnU4RUhRckw1YjJkc1hrdVAwRVgwS21uUHBSaWl5MEtCWkd3WUNqLWJ4RUU2MTljTFVPQUVub2NDdlJLMlBJcjVoZjUwdFRISk1Y?oc=5","date":"2024-04-26","type":"pipeline","source":"PR Newswire","summary":"Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndrome - PR Newswire","headline":"Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxPUkFPanBvZTNZNXVsNjA4TjVIX3UxejJRa3hkanhiQ2pMTm9LNVpIZEtTcGJmZDd0eTNLdjFFbmNZdjN0N1FBUUFKS1dZYUtDOUJqeXdPTXRxSElES1RTcGRmU3RiZFMwa2VMTjJVazdfOGpSOEhOa2Y2SmF0dnZ5S25LSTdmN09iM0l6ay1qR3BtblVqRUJRcHYtSFBJZDZoSnRzR0tPbFZGbEYzZUprMjhzdDJ6TGNQc1ZQSURUWTFWLURWcENBcjRLUDN5QjB5RUo2RDE1bFhWRTQ0RVBrWGY5cVdtZ1hpSUhVU3ZmeE9xejNwTy1MNC01SG1BZV83eTlPdFhn?oc=5","date":"2021-06-08","type":"trial","source":"GlobeNewswire","summary":"Overactive Bladder Pipeline Shows Rapid Advancements in the Clinical Trials: A Review by DelveInsight - GlobeNewswire","headline":"Overactive Bladder Pipeline Shows Rapid Advancements in the Clinical Trials: A Review by DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQVmhIWmI2aDlkVXctaDU4LWZBT09pclhVSUJGaWR5RVNFYTNpT1owN2VBbTF3cHFHUzFCRkFraE9kVHVVMUJHLW1HRjJZdUsxVjlYcmpveTVOenJ2NHlEdlJpTC1GOExTdTltSENsdlpTVlowZk93ZEJsWmszYTg5OUFoWmVrbXlNZzQ2UnVFQ2hDdWNvVG9wdzdkUEw?oc=5","date":"2020-11-13","type":"regulatory","source":"Fierce Biotech","summary":"As Urovant gears up for vibegron FDA decision, the biotech gets snapped up by Sumitovant Biopharma - Fierce Biotech","headline":"As Urovant gears up for vibegron FDA decision, the biotech gets snapped up by Sumitovant Biopharma","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}